In the last trading session, 3.48 million shares of the Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) were traded, and its beta was 1.90. Most recently the company’s share price was $5.08, and it changed around -$0.07 or -1.36% from the last close, which brings the market valuation of the company to $1.05B. BCRX currently trades at a discount to its 52-week high of $9.06, offering almost -78.35% off that amount. The share price’s 52-week low was $4.82, which indicates that the current value has risen by an impressive 5.12% since then. We note from Biocryst Pharmaceuticals Inc.’s average daily trading volume that its 10-day average is 3.94 million shares, with the 3-month average coming to 3.31 million.
Biocryst Pharmaceuticals Inc. stock received a consensus recommendation rating of Buy, based on a mean score of 1.33. If we narrow it down even further, the data shows that 0 out of 12 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 2 recommended BCRX as a Hold, whereas 8 deemed it a Buy, and 0 rated it as Underweight. Biocryst Pharmaceuticals Inc. is expected to report earnings per share of -$0.21 for the current quarter.
Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) trade information
Instantly BCRX has showed a red trend with a performance of -1.36% at the end of last trading. The performance over the last five days has remained in the red territory. The company’s shares are currently down -15.19% year-to-date, but still down -7.47% over the last five days. On the other hand, Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) is -11.03% down in the 30-day period. We can see from the shorts that 30.55 million shares have been sold at a short interest cover period of 9.31 day(s).
The consensus price target as assigned by Wall Street analysts is $19, which translates to bulls needing to increase their stock price by 73.26% from its current value. Analyst projections state that BCRX is forecast to be at a low of $14 and a high of $25.
Biocryst Pharmaceuticals Inc. (BCRX) estimates and forecasts
Biocryst Pharmaceuticals Inc. share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -32.45 percent over the past six months and at a 38.00% annual growth rate that is well above the industry average of 8.20%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 25.00% in revenue this quarter, and will report an increase of 60.00% in the next quarter. The year-over-year growth rate is expected to be 19.40%, up from the previous year.
Consensus estimates provided by 9 financial analysts predict the company will bring in an average of $86.29 million in revenue for the current quarter. 9 analysts expect Biocryst Pharmaceuticals Inc. to make $98.6 million in revenue for the quarter ending Jun 2024. The company’s sales for the same quarters a year ago were $68.78 million and $82.49 million respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 25.50%. Forecasts for the next quarter put sales growth at 19.50%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -3.73%. Biocryst Pharmaceuticals Inc. earnings are expected to increase by 46.44% in 2024, but the outlook is positive 44.80% per year for the next five years.
BCRX Dividends
Biocryst Pharmaceuticals Inc.’s next quarterly earnings report is expected to be released around May 01 and May 06.
Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.22% of Biocryst Pharmaceuticals Inc. shares, and 88.05% of them are in the hands of institutional investors. The stock currently has a share float of 89.14%. Biocryst Pharmaceuticals Inc. stock is held by 321 institutions, with Blackrock Inc. being the largest institutional investor. By Dec 30, 2023, it held 9.06% of the shares, which is about 18.68 million shares worth $94.9 million.
Vanguard Group Inc, with 8.62% or 17.76 million shares worth $90.24 million as of Dec 30, 2023, holds the second largest percentage of outstanding shares.
SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Jan 30, 2024. The former held 8.35 million shares worth $42.4 million, making up 4.05% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 6.93 million shares worth around $35.19 million, which represents about 3.36% of the total shares outstanding.
